Roche’s $2.7B Carmot bet pays off with phase 1 weight loss success for GLP-1/GIP agonist

Roche’s incursion into the obesity space seems to be paying off so far based on the first clinical readout since the drugmaker scooped up Carmot Therapeutics for $2.7 billion.

The biotech caught the attention of the Swiss pharma based on its pipeline of three molecules that could potentially challenge market leaders Eli Lilly and Novo Nordisk in the booming obesity and diabetes space. Chief among those acquired assets was CT-388, an injectable dual GLP-1/GIP receptor agonist that was already in a phase 1b trial when Roche bought Carmot in December.

Now, Roche has released 24-week data from the study showing CT-388 produced average placebo-adjusted weight loss of 18.8%. All participants who received the therapy achieved weight loss of more than 5%, Roche noted, with 85% seeing weight loss of more than 10% and 45% achieving over 20% loss.

The results suggest that CT-388 can more than hold its…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks